199 related articles for article (PubMed ID: 15728146)
1. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.
Wenzel R; Del Favero A; Kibbler C; Rogers T; Rotstein C; Mauskopf J; Morris S; Schlamm H; Troke P; Marciniak A
J Antimicrob Chemother; 2005 Mar; 55(3):352-61. PubMed ID: 15728146
[TBL] [Abstract][Full Text] [Related]
2. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.
Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS
Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747
[TBL] [Abstract][Full Text] [Related]
3. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia.
Al-Badriyeh D; Liew D; Stewart K; Kong DC
J Antimicrob Chemother; 2009 Jan; 63(1):197-208. PubMed ID: 19001450
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
[TBL] [Abstract][Full Text] [Related]
7. Economic effects of aspergillosis management in high-risk patients.
Leather H
Manag Care Interface; 2005 Apr; 18(4):46-52. PubMed ID: 15889762
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
9. Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand?
Garbino J; Schnetzler G; Roberts C
Swiss Med Wkly; 2006 Sep; 136(39-40):624-30. PubMed ID: 17086508
[TBL] [Abstract][Full Text] [Related]
10. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands.
Jansen JP; Meis JF; Blijlevens NM; van't Wout JW
Curr Med Res Opin; 2005 Oct; 21(10):1535-46. PubMed ID: 16238893
[TBL] [Abstract][Full Text] [Related]
13. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis.
Lewis JS; Boucher HW; Lubowski TJ; Ambegaonkar AJ; Day DL; Patterson TF
Pharmacotherapy; 2005 Jun; 25(6):839-46. PubMed ID: 15927903
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation.
Mattei D; Mordini N; Lo Nigro C; Ghirardo D; Ferrua MT; Osenda M; Gallamini A; Bacigalupo A; Viscoli C
Bone Marrow Transplant; 2002 Dec; 30(12):967-70. PubMed ID: 12476292
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomic assessment of therapy for invasive aspergillosis.
Luong ML; Husain S; Rotstein C
Mycoses; 2013 May; 56(3):338-49. PubMed ID: 23311989
[TBL] [Abstract][Full Text] [Related]
16. [Guideline based treatment of invasive aspergillosis].
Karthaus M
Mycoses; 2010 May; 53 Suppl 1():36-43. PubMed ID: 20433655
[TBL] [Abstract][Full Text] [Related]
17. [Experience with voriconazole in invasive aspergillosis].
Thiel E; Schwartz S
Mycoses; 2003; 46 Suppl 2():3-7. PubMed ID: 15055137
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole versus amphotericin B for invasive aspergillosis.
Blot F; Edé C; Nitenberg GM
N Engl J Med; 2002 Dec; 347(25):2080-1; author reply 2080-1. PubMed ID: 12490695
[No Abstract] [Full Text] [Related]
19. Successful treatment of brain aspergillosis with voriconazole.
Tattevin P; Bruneel F; Lellouche F; de Broucker T; Chevret S; Wolff M; Régnier B
Clin Microbiol Infect; 2004 Oct; 10(10):928-31. PubMed ID: 15373890
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.
Selleslag D; Vogelaers D; Marbaix S
Acta Clin Belg; 2009; 64(5):393-8. PubMed ID: 19999386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
